Premium
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis‐like disease in C57BL/6 mice
Author(s) -
Kozela Ewa,
Lev Nirit,
Kaushansky Nathali,
Eilam Raya,
Rimmerman Neta,
Levy Rivka,
BenNun Avraham,
Juknat Ana,
Vogel Zvi
Publication year - 2011
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2011.01379.x
Subject(s) - cannabidiol , myelin oligodendrocyte glycoprotein , experimental autoimmune encephalomyelitis , multiple sclerosis , neuroinflammation , microglia , cannabinoid , immunology , t cell , medicine , encephalomyelitis , pharmacology , neurodegeneration , inflammation , receptor , immune system , disease , cannabis , psychiatry
Cannabis extracts and several cannabinoids have been shown to exert broad anti-inflammatory activities in experimental models of inflammatory CNS degenerative diseases. Clinical use of many cannabinoids is limited by their psychotropic effects. However, phytocannabinoids like cannabidiol (CBD), devoid of psychoactive activity, are, potentially, safe and effective alternatives for alleviating neuroinflammation and neurodegeneration.